Senses Disorder TRIZ Cases

In vivo confocal microscopy quantifies ocular physical features to enable targeted treatment selection for dry eye syndrome.

Segmented culture media and signaling modulators induce iPSCs into functional RPE cells, reducing production time from months to weeks.

Honokiol polyphenols cross the blood-brain barrier to protect hair cells, preventing cisplatin-induced ototoxicity without compromising antitumor efficacy.

Detecting anti-thyroid peroxidase antibodies identifies patients at risk for thyroid disorders before lymphocyte depleting therapy.

Engineered antibodies isolate free IL-18 to resolve detection specificity issues in inflammatory disease diagnostics.

Au18(L-NIBC)14 gold cluster molecule delivers targeted therapeutic action against multiple sclerosis and Alzheimer's disease.

Antibodies targeting extracellular epitopes on the CB1 receptor deliver peripheral modulation while avoiding psychiatric adverse effects from brain penetration.

Pyrimidine derivatives inhibit mPGES-1 to suppress PGE2 biosynthesis, avoiding gastric injury and thrombosis risks linked to COX inhibitors.

Topical pooled human immunoglobulin G neutralizes pathogenic autoantibodies to treat inflammatory ocular diseases without corticosteroid side effects.

Substituted fused pyrimidine compounds act as potent antagonists of A2B and A1 adenosine receptors.

Segmented synthesis of SGLT inhibitors via alkyl lithium and BF3OEt2 intermediaries avoids systemic side effects of broad antidiabetic agents.

Isoquinoline derivatives inhibit Rho kinase and myosin light chain phosphorylation, addressing inadequate specificity in current hypertension treatments.

Targeting the first extracellular loop of Kv1.3 channels reduces potassium efflux by 70% while preserving protective immune responses.

5-substituted isoindole compounds inhibit angiogenesis to treat refractory cancers while minimizing toxic side effects from conventional therapies.

Segmenting TGF-beta into a stable 20-amino acid sequence overcomes short half-life and high production costs.

Mixed herbal extract composition inhibits advanced glycation endproducts formation to prevent diabetic retinopathy progression.

Selective phenylethylamino channel modulators reduce MAO inhibitory activity, minimizing hypertensive crisis risks in chronic treatments.

Substituted pyrazolyl heteroaryls resolve metabolic stability and selectivity trade-offs by localizing specific R2 and R3 substituents on the core scaffold.

Modified cyclodextrins solubilize pazopanib, resolving formulation stability issues.

ANGPTL7 inhibitors reduce intraocular pressure to treat glaucoma, while genetic testing enables dosage adjustments that minimize adverse effects.

CIRP inhibitor peptides resolve inflammation management contradictions by reducing proinflammatory cytokines to enhance wound healing success.

Omidenepag dilates retinal blood vessels to improve flow while protecting nerve cells from apoptosis.

Dynamic ureidopyrimidinone crosslinks extend hyaluronic acid residence time in synovial joints while avoiding pseudoseptic reactions from chemical crosslinking.

Modular purine derivatives with Ki values below 1.0 µM resolve insufficient receptor activation in obstructive airways diseases.

Mutating or deleting the E-peptide sequence prevents endogenous protease cleavage, allowing modified IGF polypeptides to remain stable and bioactive in serum.

Chemically modified double-stranded RNA molecules enhance serum stability and cellular uptake to resolve poor biodistribution in DDIT4-targeted therapies.

A mitochondria composition with a biocompatible carrier restores gingival fibroblast function.

Pharmaceutical compositions containing sazetidine or varenicline modulate nicotinic acetylcholine receptors, reducing attentional fixation on tinnitus signals.

Amino acid substitutions at positions 31, 176, and 306 stabilize modified LCAT enzymes to treat low HDL levels in patients unresponsive to statins.

Hypertonic pantothenol and cellulose composition prevents mucosa drying and inflammation without sympathomimetic side effects.

Formula I pyrazolo-oxazinyl compounds address inadequate management of negative and cognitive symptoms in bipolar disorder and schizophrenia.

Merging TRPM8 and nAChR agonists into one composition resolves the trade-off between effective weight reduction and severe side effects like nausea.

A semifluorinated alkane composition dissolves prostaglandin analogues for topical ophthalmic use.

Low-dose SGLT2 inhibitor treats age-related maculopathy by suppressing retinal sodium and glucose uptake without inducing hypoglycemia.

Amino acid substitutions in the Fc fragment boost FcRn and Fc receptor affinity, extending half-life and therapeutic efficacy.

Low surfactant concentration creates a preservative-free, flocculated suspension that resists rapid settling and injects smoothly through small needles.

Inhibiting negative regulators of the mTOR pathway reactivates protein synthesis, overcoming diminished intrinsic regenerative capacity in adult CNS neurons.

Carboxylic acid substituted pyrrolidine compounds enhance glycemic control while reducing adverse events associated with existing anti-diabetic agents.

Administering neuroprotective compounds to patients receiving anti-VEGF injections.

Dsg2-derived peptides block angiogenesis pathways by targeting the EC2 domain to inhibit vasculogenic mimicry.

C-13 tagging on retinoid cores eliminates photoisomerization degradation while providing strong fluorescence signals for cell monitoring.

Reducing atropine concentration to 0.05% delays myopia onset while minimizing blurred near vision and photophobia side effects.